Serial Number: 09/424,181

REMARKS

Favorable reconsideration of this application as presently amended is

respectfully requested. Claims 2-8 and 11 are pending. Claim 1 is canceled and

claims 2-8 are amended. No new matter is added.

Claims 1-8 and 11 are rejected under 35 U.S.C. § 112, second paragraph. The

Examiner is thanked for pointing out the specific objectionable language. Claim 1 has

been canceled and claims 2-8 have been amended to comply with the requirements of

35 U.S.C. § 112, second paragraph and to more distinctly define the subject matter of

the present invention. Thus, the rejection under § 112 has been obviated and should

be withdrawn.

Claim 1 is rejected under 35 U.S.C. § 102(e) as being anticipated by U.S.

Patent No. 5,798,249 to Braxton. Claim 1 is also rejected under 35 U.S.C. § 102(e) as

being anticipated by U.S. Patent No. 6,309,644 to Chandreshekar. Claim 1 is also

rejected under 35 U.S.C. § 102(b) as being anticipated by Ryser (PNAS 91, 4559,

1994). Claim 1 is also rejected under 35 U.S.C. § 102(b) as being anticipated by

Morjana (Biochem 30, 4985, 1997). These rejections are obviated by the cancellation

of claim 1.

Since the § 112 rejection of claims 1-8 and 11 has been obviated and there are

no pending rejections of claims 2-8 and 11, the allowance of claims 2-8 and 11 is

respectfully requested.

-3-

Serial Number: 09/424,181

If the Examiner has any questions or concerns regarding the present response, the Examiner is invited to contact Steven J. Prewitt at 703-591-2664. In view of the foregoing, it is respectfully submitted that this application is in condition for allowance, and favorable action is respectfully solicited.

Respectfully submitted,

Steven J. Prewitt Reg. No. 45,023

JAGTIANI + GUTTAG Democracy Square Business Center 10379-B Democracy Lane Fairfax, Virginia 22030 (703) 591-2664

June 24, 2002

In re Application of:	TECH :
ROGELJ et al.	Examiner: Lukton, D.
Serial Number: 09/424,181	2° 6 1
Filed: November 10, 1999) Art Unit: 1653
For: Inhibition of Cell Surface Protein Disulfide Isomerase) Docket No.: UNME-0054-1

Director of the U.S. Patent and Trademark Office Washington, D.C. 20231

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Sir:

Below are the amendments in the accompanying Amendment for the aboveidentified application shown in redlined format:

IN THE CLAIMS

Please cancel claim 1, without prejudice or disclaimer.

Please amend the claims, without prejudice or disclaimer, as indicated below:

2. (Amended) An membrane-impermeable inhibitor of protein disulfide isomerase (PDI) according to Claim 1 of having the formula:

wherein at least one of R and R' is a charged ligand containing from 1 to 6 carbon atoms.

3. (Amended) An inhibitor according to Claim 2, wherein the charged ligand contains at least one sulfonate SO_3 group.

- 4. (Amended) An inhibitor according to Claim 2, wherein the ligand is a straight chain or branched alkyl group containing 1, 3, 4, or 6 carbon atoms and at least one $S\Omega_3$ -sulfonate group.
- 5. (Amended) An inhibitor according to Claim 2, wherein the ligand is an aryl group containing at least one SO_3 sulfonate group.
- 6. (Amended) The inhibitor of Claim 5, wherein the SO_3 sulfonate group is attached to a ring carbon atom.
- 7. (Amended) The inhibitor of Claim 6, wherein the SO_3 -sulfonate group is attached to the ring carbon atom via a C_1 - C_6 -alkylene group.
- 8. (Amended) An membrane-impermeable inhibitor of protein disulfide isomerase (PDI) according to claim 1 of having the formula:

wherein R is H or alkyl.

.

11. An inhibitor according to Claim 2, wherein one of R or R' is an uncharged H or C_1 - C_6 -alkyl ligand.